ArticleTheranostics2020
Alpha radioimmunotherapy using
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 44 citations in OpenAlex.
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Establishment ofMolecular pharmaceutics · 2026Article
- PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform.Cellular & molecular biology letters · 2026Article
- PretargetedTheranostics · 2026Article
- Article
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Trends in nanobody radiotheranostics.European journal of nuclear medicine and molecular imaging · 2025Review
- Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation.Cell reports. Medicine · 2025Review
- Comparison of targeting two antigens (GPA33 versus HER2) forTheranostics · 2025Article
- Article
- Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy.Acta biochimica et biophysica Sinica · 2024Review
- Click Chemistry Enables [Bioconjugate chemistry · 2024Article
- Nuclear Imaging of Bispecific Antibodies on the Rise.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.EJNMMI radiopharmacy and chemistry · 2024Review
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Efficacy of HER2-Targeted IntraperitonealJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Pretargeted Radioimmunotherapy of Ovarian Cancer withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 1 country.
Sarah M ChealMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael R McDevittDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Brian H SantichDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Mitesh PatelMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Guangbin YangOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY.
Edward K FungDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
Darren R VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Meghan BellMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Afruja AhadMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniela Burnes VargasMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Blesida PunzalanMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Naga Vara Kishore PillarsettyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Hong XuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Hong-Fen GuoDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Sébastien MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, NY.
Adam O MichelLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, NY.
Alessandra PiersigilliLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, NY.
David A ScheinbergMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Ouathek OuerfelliOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY.
Nai-Kong V CheungMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Steven M LarsonMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Memorial Sloan Kettering Cancer Center · USWeill Cornell Medicine · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9MUnderstanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2MRECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8MDOTA-based pre-targeting of alpha emittersR01CA233896 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE · 2019 to 2023
$3.4MOrganic Synthesis at the Service of Biology and MedicineR50CA243895 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ouathek Ouerfelli · 2019 to 2026
$1.9MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA086438NCI NIH HHS R01 CA055349NCI NIH HHS R01 CA233896NCI NIH HHS R35 CA241894NCI NIH HHS R50 CA243895
Abstract
This is the initial report of an α-based pre-targeted radioimmunotherapy (PRIT) using
Indexed as
ActiniumAlpha ParticlesAnimalsCell Line, TumorDose-Response Relationship, RadiationFemaleHalf-LifeHeterocyclic Compounds, 1-RingHumansIndium RadioisotopesMiceNanoparticlesNeoplasmsRadioimmunotherapyRadiopharmaceuticalsRadiotherapy Dosage1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acidActiniumActinium-225Heterocyclic Compounds, 1-RingIndium-111Indium RadioisotopesRadiopharmaceuticalsAc-225pretargeted radioimmunotherapypretargetingradioimmunotherapyTAT
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.